Leica Biosystems Finalizes Acquisition of Devicor Medical Products

German cancer diagnostics maker Leica Biosystems said Wednesday that it has completed its acquisition of Devicor Medical Products. The Cincinnati, Ohio-based Devicor, which specializes in breast biopsy instruments and consumables, was previously owned by private equity firm GTCR.

Under the deal, which was agreed to Oct. 28, Devicor will continue to operate as a standalone business under the leadership of CEO Tom Daulton. Financial terms and conditions were not disclosed.

Devicor’s annual revenues are in the $170 million range, led by its Mammotome breast biopsy system, a minimally invasive technique that uses x-ray and other medical imaging to help the physician guide a probe into suspicious areas of the breast, according to Leica.

Leica President Matthias Weber said the company’s biosystems products address key steps across the anatomic pathology lab workflow. “The addition of Devicor’s market-leading biopsy products, especially Mammotome, allows us to further integrate that workflow from the source, starting with the patient and the biopsy sample.” — Kellen Owings

Subscribe to Devices & Diagnostics Letter for complete coverage of the medical devices industry. Click here for more information.